Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Loss and Comprehensive Loss

v3.23.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue $ 0 $ 0
Expenses:    
Research and development 28,088 45,985
General and administrative 14,514 19,462
Operating expenses 42,602 65,447
Other income :    
Interest income 788 94
Foreign exchange gain/(loss) (9) (1)
Total other income 779 93
Net loss (41,823) (65,354)
Other comprehensive loss:    
Unrealized loss on securities available-for-sale (2) 0
Total comprehensive loss $ (41,825) $ (65,354)
Basic loss per common share $ (0.45) $ (0.73)
Diluted loss per common share $ (0.45) $ (0.73)
Weighted average number of common shares outstanding used in the calculation of    
Weighted Average Number of Shares Outstanding, Basic 92,267 89,086
Weighted Average Number of Shares Outstanding, Diluted 92,267 89,086